NeuroPace (NPCE)
(Real Time Quote from BATS)
$8.02 USD
+0.32 (4.16%)
Updated Jul 16, 2024 12:56 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NPCE 8.02 +0.32(4.16%)
Will NPCE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NPCE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NPCE
Globus Medical (GMED) Q1 Earnings and Revenues Beat Estimates
Thermo Fisher Scientific (TMO) Tops Q1 Earnings and Revenue Estimates
NPCE: What are Zacks experts saying now?
Zacks Private Portfolio Services
RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates
Alphatec (ATEC) Reports Q3 Loss, Tops Revenue Estimates
Accuray (ARAY) Reports Q1 Loss, Misses Revenue Estimates
Other News for NPCE
Strong Sales Growth and Strategic Initiatives Justify Buy Rating for NeuroPace
NeuroPace post Q1 move 'overdone,' says Lake Street
NeuroPace post Q1 move 'overdone,' says Lake Street
NeuroPace to Participate in Two Healthcare Conferences in May
NeuroPace, Inc. (NPCE) Q1 2024 Earnings Call Transcript